Biosimilars in dermatology

Biosimilars in Dermatology: Current Situation (Part I).

The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this article, we review regulatory issues related to the ...

Biosimilars

Imaging techniques in dermatology

Since the discovery of X-rays, the use of imaging technology has continued to play an important role in medicine. Technological advancements have led to the development of various imaging modalities, most of which have been used to image organs deep within the human body. More recently, attention has focused on the application of imaging technology for evaluation of the skin. A variety of techn...

Biosimilars in Crohn's disease.

The patent for some biological medicines used in the treatment of Crohn's disease are close to expire. Biosimilars are biologicals sufficiently similar to a biopharmaceutical already approved by a regulatory agency.1 Several companies are developing biosimilars to tumor necrosis factor and the first biosimilar submitted to the European agency for the treatment of rheumatoid arthritis was develo...

Macrolides in dermatology

Erythromycin was the first macolide discovered in 1952. In 1990s new macrolides including clarithromycin, azithromycin, and dirithromycin were introduced to the market. We provide a review of their structure, pharmacokinetics, mechanisms of action, and indications in dermatology.